1. Scrip
  2. >>Business

Sun Seeks Partner For GLP-I Asset, Legal Challenge Clouds Alopecia Drug Launch

 
• By Anju Ghangurde

Sun’s chief Dilip Shanghvi talks about partnering intent for the firm’s GLP-1 candidate, which he hopes can complete studies in an accelerated timeframe, while legal action in the US has a cast a shadow on launch timelines of the Indian drug maker's alopecia areata treatment.

Sun mulls partnering option for promising GLP-1 candidate • Source: Shutterstock

Sun Pharmaceutical Industries Ltd., is eying the partnering route as it seeks to advance into the high-profile glucagon-like peptide-1 (GLP-1) receptor agonist space, currently witnessing huge excitement as a therapeutic class for obesity.

Sun’s specialty pipeline includes a promising early stage GLP-1 receptor agonist, GL0034(utreglutide), indicated for type 2 diabetes and obesity, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?